Clinical trial · Observational
ISP-TACE Versus TACE for HCC With PVTT
Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: Survival Benefit of Transarterial Chemoembolization in Combination With Irradiation Stent Placement
NCT03108248CI-TRIAL-00026923completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) remains modest. This study aimed to investigate whether TACE in combination with irradiation stent placement (ISP) could prolong the survival in patients with HCC and PVTT.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
| Portal Vein Tumor Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ethiodized oil; doxorubicin;Gelfoam; | Drug | — | UNRESOLVED |
| stent; idoine-125 | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- ISP-TACE group
- description
- During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
- interventionNames
- Drug: ethiodized oil; doxorubicin;Gelfoam;
- label
- TACE group
- description
- During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
- interventionNames
- Drug: ethiodized oil; doxorubicin;Gelfoam;
- Device: stent; idoine-125
Primary outcomes (1)
- measure
- survival
- timeFrame
- 0-6 years
- description
- The overall survival (OS) was defined as the time from first treatment to death or the patient's last follow up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * (1) newly diagnosed HCC with type II or III PVTT, (2) Child-Pugh classification grade A or B, (3) Eastern Cooperative Oncology Group (ECOG) performance status score 0-2. Exclusion Criteria: * (1) type I or IV PVTT, (2) received sorafenib, systemic chemotherapy, or external radiotherapy during the treatment, (3) suffered from malignancy other than HCC, (4) with an incomplete data.
References
Publications (0)
Data not yet available
No reference posted for this study.